Islet Sciences
Islet Sciences is a Raleigh-based biotech developing micro-encapsulated porcine islet cell suspensions for abdominal injection to treat insulin-dependent diabetes. The company is delisted to OTC Pink and appears pre-commercial with no disclosed revenue or customers.
- Company typePrivate
- Founded1994
- HeadquartersRaleigh, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Islet Sciences does
Islet Sciences is a for-profit, Raleigh, North Carolina-based biotechnology company founded in 1994 that is developing a vialed suspension of micro-encapsulated porcine islets intended for injection into the abdominal cavity, a xenotransplantation-based approach targeting insulin-dependent diabetes. The company's core technology centers on micro-encapsulation of porcine islet cells, a biologic-device platform positioned for a regulated FDA pathway rather than a software or device-software product. Its capital-markets history includes a listing transition to OTC Pink under symbol ISLT, and its corporate domain isletsciences.com is currently listed for sale on HugeDomains, indicating operational discontinuity or dormant status.
The company's business model is not commercially active in the input data: there are no disclosed customers, no pricing model, no product launch milestones, and no revenue figures. Documented strategic activity is limited to the February 2012 acquisition of DiaKine Therapeutics and a single $695,000 funding round in February 2014. Leadership on record consists of Rick Egan as CFO and William Wilkison as COO, and headcount is reported in the 11-50 employee band. No AI/ML capabilities, partnerships, certifications, or regulatory milestones beyond the implied biologics pathway are evidenced.
Islet Sciences firmographics
Firmographics- Name
- Islet Sciences
- Website
- http://isletsciences.com
- Company type
- Private
- Founded year
- 1994
- Headcount range
- 11–50 employees
- Short description
- Islet Sciences is a Raleigh-based biotech developing micro-encapsulated porcine islet cell suspensions for abdominal injection to treat insulin-dependent diabetes. The company is delisted to OTC Pink and appears pre-commercial with no disclosed revenue or customers.
- Ownership category
- akta.pro rank
Islet Sciences industry classification
Industry- Product category
- Cell Therapy Biologics
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Patch Pumps & Wearable Insulin Delivery (HLAHAHAC)
Keywords
Where Islet Sciences is headquartered
LocationHeadquarters
- HQ city
- Raleigh
- HQ country
- United States
- HQ region
- North America
Markets served
Islet Sciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Islet Sciences product offering
Product offeringCore offering
Islet Sciences develops a vialed suspension of micro-encapsulated porcine islets intended for injection into the abdominal cavity, focused on a cell-based therapeutic approach for diabetes. The company's work centers on xenogeneic islet cell encapsulation as a potential treatment modality for insulin-dependent patients.
Differentiator
Problem solved
Functional benefit
Products and services
- Micro-encapsulated Porcine Islet Suspension
Companies that use Islet Sciences
Customer profileIdeal customer profiles1 record
Islet Sciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Islet Sciences partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights2 records
Islet Sciences competitors and assessment
Company assessmentDirect peers
- ViaCyte: ViaCyte is the most directly comparable peer — a cell therapy developer of encapsulated stem-cell-derived islet cells (PEC-Direct, VC-02) implanted for Type 1 diabetes. It targets the same encapsulated-islet-for-diabetes category that Islet Sciences is pursuing, though ViaCyte uses stem-cell-derived rather than xenogeneic porcine islets.
- Sernova Biotherapeutics: Sernova develops an implantable Cell Pouch system with donor islets (and increasingly stem-cell-derived cells) for Type 1 diabetes. It competes in the same cell replacement therapy category and pursues a similar immune-isolation strategy for sustained insulin independence.
Broad incumbents
- Vertex Pharmaceuticals (VX-880 / CTX211): Vertex acquired Semma Therapeutics and is advancing stem-cell-derived islet cell therapy (VX-880 / zimislecel) for Type 1 diabetes. It is a broad incumbent now leading the encapsulated/encapsulated-equivalent islet therapy race and a benchmark for the category Islet Sciences targets.
Emerging players
- Beta-O2 Technologies: Beta-O2 develops the ßAir macroencapsulation device for implantation of allogeneic islet cells, providing immune isolation for Type 1 diabetes. It is an emerging player in the same encapsulated islet cell therapy space with a smaller scale and earlier stage than Islet Sciences' lead asset.
- Defymed: Defymed is developing the MailPan macroencapsulation device for pancreatic cell transplantation in diabetes. It is an emerging European player in the same encapsulated-cell-therapy-for-diabetes category with a device-centric rather than cell-centric approach.
- PharmaCyte Biotech: PharmaCyte is developing a cellulose-based live-cell encapsulation technology (Cell-in-a-Box) applied initially to insulin-producing cells for diabetes. It is an emerging player using a comparable encapsulation platform strategy in the same therapeutic area.
Others
- Dexcom: Dexcom is a leading continuous glucose monitor (CGM) manufacturer and serves the same Type 1 diabetes end patient. It is not a direct competitor to Islet Sciences' cell therapy but is the standard-of-care diagnostic/adjunct device that any islet replacement therapy would be benchmarked against.
- Tandem Diabetes Care: Tandem develops insulin pumps and automated insulin delivery systems for Type 1 diabetes. It is an adjacent device player that addresses the same patient population through the alternative insulin-pump pathway rather than cell replacement.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights4 records
Customer concentration
Islet Sciences social profiles
Digital presenceIslet Sciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Islet Sciences leadership team
Management profileNumber of profiles
Profiles2 records
Islet Sciences funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Islet Sciences M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Islet Sciences
What does Islet Sciences do?
Islet Sciences develops a vialed suspension of micro-encapsulated porcine islets intended for injection into the abdominal cavity, focused on a cell-based therapeutic approach for diabetes. The company's work centers on xenogeneic islet cell encapsulation as a potential treatment modality for insulin-dependent patients.
When was Islet Sciences founded?
Islet Sciences was founded in 1994. It employs 11 to 50 people.
Where is Islet Sciences based?
Islet Sciences is headquartered in Raleigh, United States, in the North America region.
Who are Islet Sciences's main competitors?
Direct peers on record are ViaCyte and Sernova Biotherapeutics. Vertex Pharmaceuticals (VX-880 / CTX211) is listed as a broad incumbent. Emerging players are Beta-O2 Technologies, Defymed and PharmaCyte Biotech. Others are Dexcom and Tandem Diabetes Care.
Does Islet Sciences have an API?
No public API is recorded for Islet Sciences.
What industry is Islet Sciences in?
Islet Sciences's product category is Cell Therapy Biologics. Its primary akta.pro industry code is HLAHAHAC, Patch Pumps & Wearable Insulin Delivery. Its NAICS code is 339113 and its SIC code is 3841.